X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AM E3-SG3249, is a CRLF2/TLSP inhibitor, a preclinical candidate which is being investigated for the treatment of philadelphia chromosome-like acute lymphoblastic leukemia.
Lead Product(s): AM E3-SG3249
Therapeutic Area: Oncology Product Name: AM E3-SG3249
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
The collaboration aims to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rainwater Charitable Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 12, 2023
Details:
The collaboration aims to evaluate the opportunities for peptide-based therapeutic candidates across multiple indications through the well-established phage and mRNA display platforms.
Lead Product(s): Peptide Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 22, 2023
Details:
Under the agreement, Antios will purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) which is being developed for the treatment of HBV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Antios Therapeutics
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 15, 2021
Details:
IRBM will leverage previous research into SARS to contribute to identifying and developing a potential treatment of SARS-CoV-2, as well as other future life-threatening coronavirus strains.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
